Transdiagen
- Company typePrivate
- Founded-
- HeadquartersCardiff, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Transdiagen does
Transdiagen is a clinical-stage biopharmaceutical company headquartered at 19 Windsor Place, Cardiff, United Kingdom, that applies proprietary wound gene signatures to power an AI-driven diagnostics and therapeutics platform for patients with chronic wounds. The company's core technology analyzes gene expression patterns through an AI platform to generate diagnostics and develop curative therapies aimed at chronic wound healing, tissue regeneration, and antibiotic-resistant wound infections. Its product surface is currently described as a single AI-powered diagnostics platform built around novel wound gene signatures and models, with no commercial product on market and no disclosed pricing model.
Transdiagen firmographics
Firmographics- Name
- Transdiagen
- Legal name
- Transdiagen
- Website
- https://transdiagen.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Transdiagen industry classification
Industry- Product category
- Wound Care Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), Services-Health Services (8000)
- akta.pro primary industry
- Wound Care & Ulcer Management (HLAKACAN)
- akta.pro secondary industries
- Condition-specific Digital Therapeutics (DTx) (HLACANAA), Diagnostic & Triage Decision Support (HLACAGAA), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)
Keywords
Where Transdiagen is headquartered
LocationHeadquarters
- HQ city
- Cardiff
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Transdiagen business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Transdiagen product offering
Product offeringCore offering
Transdiagen operates a clinical-stage AI-powered diagnostics platform that utilizes proprietary wound gene signatures and models to generate diagnostics for patients with chronic wounds. The platform supports data-driven, evidence-based development of curative therapies and tissue regeneration treatments, and is being used in research collaborations to provide functional insights into the mode of action of wound care products.
Product overview
Transdiagen is a clinical-stage biopharmaceutical company operating as a single unified platform. The company's core offering is an AI-powered diagnostics platform that uses wound gene signatures and models to generate diagnostics and curative therapies for patients with chronic wounds. The technology focuses on precision medicine approaches to tissue regeneration and chronic wound healing.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-Powered Diagnostics Platform A clinical-stage AI platform that analyzes wound gene signatures and gene expression data to generate diagnostics for patients with chronic wounds and inform the development of curative therapies and tissue regeneration treatments. It is targeted at MedTech and wound care companies seeking data-driven, evidence-based insights into wound treatment modes of action.
Companies that use Transdiagen
Customer profileSegments1 record
Ideal customer profiles1 record
Transdiagen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature1 record
Transdiagen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Mölnlycke Health CarecoreMölnlycke Health Care, a MedTech company specializing in wound care, entered a research collaboration with Transdiagen. The partnership leverages Transdiagen's novel wound gene signatures and models to explore Mölnlycke's existing wound care products and generate functional insights into the mode of action of innovative wound treatment solutions. Both companies described the collaboration as a new chapter in data-driven, evidence-based product development for complex wounds, with the partnership expected to drive future innovation in an under-resourced area of wound care.
Scale indicators1 record
Recent moves3 records
Expansion highlights4 records
Transdiagen competitors and assessment
Company assessmentRegional players
- Cardinal Health (Medical/Wound Care): Cardinal Health distributes wound care products and provides post-acute care solutions, primarily in the US market. Comparable as a distribution/commercial channel peer relevant to chronic-wound product commercialization pathways.
Broad incumbents
- Integra LifeSciences: Integra LifeSciences offers a portfolio including regenerative wound care technologies (e.g., Integra dermal regeneration templates) and surgical instruments. Comparable as an incumbent with overlap in advanced wound healing and tissue regeneration.
- 3M Health Care: 3M Health Care (now Solventum for the health-care spin-off) operates a substantial wound care and skin health business. Comparable as a broad incumbent in the chronic-wound dressings and care market.
- Smith & Nephew: Smith & Nephew is a large MedTech incumbent with a substantial Advanced Wound Management franchise serving chronic-wound patients globally. It overlaps directly with Transdiagen's chronic-wound focus and is a benchmark for commercialization scale in the same category.
- ConvaTec: ConvaTec is a global medical products company with a leading Advanced Wound Care portfolio. It targets the same chronic-wound patient population as Transdiagen with established dressings and skin substitutes, making it a relevant incumbent peer.
- Coloplast: Coloplast operates a significant Wound Care business alongside ostomy and continence care, serving chronic-wound patients with dressings and skin care solutions. It is comparable as a broad incumbent addressing the same chronic-wound market.
Direct peers
- Organogenesis: Organogenesis is a regenerative medicine company commercializing cell-based and tissue-based products for chronic wounds (e.g., Apligraf, Dermagraft). It is comparable because both companies pursue curative/regenerative therapies for chronic-wound patients, albeit via different modalities.
- Mölnlycke Health Care: Mölnlycke Health Care is a global MedTech company specializing in wound care and surgical solutions. It is directly comparable because Transdiagen's first major research collaboration is with Mölnlycke, and both target the chronic-wound care market with evidence-based product development.
- MiMedx: MiMedx develops and commercializes regenerative wound care and surgical biologics from placental tissue. It is comparable because both companies are targeting chronic-wound healing through advanced biologic/regenerative approaches.
Emerging players
- Healios (Helios): Healios is a digital health and diagnostics platform focused on wound care outcomes using imaging and AI. Comparable as an emerging player applying AI/data-driven approaches to chronic-wound assessment, intersecting with Transdiagen's gene-signature AI diagnostic platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Transdiagen social profiles
Digital presenceTransdiagen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Transdiagen leadership team
Management profileNumber of profiles
Profiles5 records
Transdiagen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Transdiagen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Transdiagen
What does Transdiagen do?
Transdiagen operates a clinical-stage AI-powered diagnostics platform that utilizes proprietary wound gene signatures and models to generate diagnostics for patients with chronic wounds. The platform supports data-driven, evidence-based development of curative therapies and tissue regeneration treatments, and is being used in research collaborations to provide functional insights into the mode of action of wound care products.
Is Transdiagen a public or private company?
Transdiagen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Transdiagen founded?
Transdiagen was founded in -1. It employs 1 to 10 people.
Where is Transdiagen based?
Transdiagen is headquartered in Cardiff, United Kingdom, in the Europe region.
Who are Transdiagen's main competitors?
Cardinal Health (Medical/Wound Care) is listed as a regional player. Broad incumbents are Integra LifeSciences, 3M Health Care, Smith & Nephew, ConvaTec and Coloplast. Direct peers are Organogenesis, Mölnlycke Health Care and MiMedx. Healios (Helios) is listed as an emerging player.
Does Transdiagen have an API?
No public API is recorded for Transdiagen.
What industry is Transdiagen in?
Transdiagen's product category is Wound Care Diagnostics. Its primary akta.pro industry code is HLAKACAN, Wound Care & Ulcer Management, with a secondary code of HLACANAA, Condition-specific Digital Therapeutics (DTx). Its NAICS code is 621511 and its SIC code is 8071.